On Mar. 25, 2020, CHF Solutions announced the use of its Aquadex therapy in the treatment of patients infected with the coronavirus COVID-19.

In the last week, critically ill patients in New York City and the state of Georgia, who have been infected with COVID-19, were treated for volume overload using the Aquadex system.  CHF Solutions expected increased demand for this ultrafiltration therapy as the rate of affected patients that are infected with COVID-19 is likely to increase.

The World Health Organization (WHO) had released a protocol for treating patients infected with COVID-19, highlighting the need for effective fluid management treatment strategies when caring for the critical patient population because the risk of volume overload is very high.

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics.

All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.